Methylene blue administration in septic shock: a clinical trial.

Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, Kahn RJ, Vincent JL

Critical care medicine1 Feb 1995Cited by 159 (Europe PMC)

PMID7532559DOI10.1097/00003246-199502000-00010PepBankPUB-07532559

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with septic shock, methylene blue increased mean arterial pressure from baseline at 60 mins.
In plain wordsMethylene blue increased mean blood pressure compared with baseline in patients with septic shock.
Peptide
Methylene blue
Outcome
IncreaseMean arterial pressure
Study
n = 14
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 mg/kg · intravenous · Short-term infusionAs given in this study (human).
Measurements
Mean arterial pressure
61.1 mm Hg
baseline, mean (SD 7.6)
Mean arterial pressure
71.7 mm Hg
60 mins after infusion, mean (SD 12.0)
Source sentences
Summary
Methylene blue administration was followed by a progressive increase in mean arterial pressure (from 61.1 +/- 7.6 to 71.7 +/- 12.0 mm Hg at 60 mins, p < .01).
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective clinical trial.
Summary · context
Fourteen patients with severe septic shock requiring adrenergic therapy.
Summary · context
Hemodynamic measurements were obtained at baseline, and 30, 60, and 90 mins after the infusion of 2 mg/kg of methylene blue.
Report a problemFND-0753255901
02HumanNon-randomized trialEfficacy outcome
In patients with septic shock, pulmonary arterial pressure did not change significantly after methylene blue.
In plain wordsLung artery pressure did not change significantly from baseline after methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
No significant changePulmonary arterial pressure
Study
n = 14
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Studied dose
2 mg/kg · intravenous · Short-term infusionAs given in this study (human).
Source sentences
Summary
Pulmonary arterial pressure, cardiac filling pressures, cardiac output oxygen delivery, and oxygen consumption were not significantly affected.
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective clinical trial.
Summary · context
Fourteen patients with severe septic shock requiring adrenergic therapy.
Summary · context
Hemodynamic measurements were obtained at baseline, and 30, 60, and 90 mins after the infusion of 2 mg/kg of methylene blue.
Report a problemFND-0753255902
03HumanNon-randomized trialEfficacy outcome
In patients with septic shock, cardiac filling pressures did not change significantly after methylene blue.
In plain wordsHeart filling pressures did not change significantly from baseline after methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
No significant changeCardiac filling pressures
Study
n = 14
Comparator
Baseline
Outcome group
Heart function · Cardiovascular
Studied dose
2 mg/kg · intravenous · Short-term infusionAs given in this study (human).
Source sentences
Summary
Pulmonary arterial pressure, cardiac filling pressures, cardiac output oxygen delivery, and oxygen consumption were not significantly affected.
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective clinical trial.
Summary · context
Fourteen patients with severe septic shock requiring adrenergic therapy.
Summary · context
Hemodynamic measurements were obtained at baseline, and 30, 60, and 90 mins after the infusion of 2 mg/kg of methylene blue.
Report a problemFND-0753255903
04HumanNon-randomized trialEfficacy outcome
In patients with septic shock, cardiac output did not change significantly after methylene blue.
In plain wordsHeart blood output did not change significantly from baseline after methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
No significant changeCardiac output
Study
n = 14
Comparator
Baseline
Outcome group
Heart function · Cardiovascular
Studied dose
2 mg/kg · intravenous · Short-term infusionAs given in this study (human).
Source sentences
Summary
Pulmonary arterial pressure, cardiac filling pressures, cardiac output oxygen delivery, and oxygen consumption were not significantly affected.
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective clinical trial.
Summary · context
Fourteen patients with severe septic shock requiring adrenergic therapy.
Summary · context
Hemodynamic measurements were obtained at baseline, and 30, 60, and 90 mins after the infusion of 2 mg/kg of methylene blue.
Report a problemFND-0753255904
05HumanNon-randomized trialEfficacy outcome
In patients with septic shock, oxygen delivery did not change significantly after methylene blue.
In plain wordsOxygen delivery did not change significantly from baseline after methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
No significant changeOxygen delivery
Study
n = 14
Comparator
Baseline
Outcome group
Blood oxygenation and oxygen transport · Whole body
Studied dose
2 mg/kg · intravenous · Short-term infusionAs given in this study (human).
Source sentences
Summary
Pulmonary arterial pressure, cardiac filling pressures, cardiac output oxygen delivery, and oxygen consumption were not significantly affected.
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective clinical trial.
Summary · context
Fourteen patients with severe septic shock requiring adrenergic therapy.
Summary · context
Hemodynamic measurements were obtained at baseline, and 30, 60, and 90 mins after the infusion of 2 mg/kg of methylene blue.
Report a problemFND-0753255905
06HumanNon-randomized trialEfficacy outcome
In patients with septic shock, oxygen consumption did not change significantly after methylene blue.
In plain wordsOxygen consumption did not change significantly from baseline after methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
No significant changeOxygen consumption
Study
n = 14
Comparator
Baseline
Outcome group
Blood oxygenation and oxygen transport · Whole body
Studied dose
2 mg/kg · intravenous · Short-term infusionAs given in this study (human).
Source sentences
Summary
Pulmonary arterial pressure, cardiac filling pressures, cardiac output oxygen delivery, and oxygen consumption were not significantly affected.
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective clinical trial.
Summary · context
Fourteen patients with severe septic shock requiring adrenergic therapy.
Summary · context
Hemodynamic measurements were obtained at baseline, and 30, 60, and 90 mins after the infusion of 2 mg/kg of methylene blue.
Report a problemFND-0753255906
07HumanNon-randomized trialEfficacy outcome
In patients with septic shock, methylene blue increased left ventricular stroke work after 60 mins.
In plain wordsMethylene blue increased left heart pumping work compared with baseline in patients with septic shock.
Peptide
Methylene blue
Outcome
IncreaseLeft ventricular stroke work
Study
n = 14
Comparator
Baseline
Outcome group
Heart function · Cardiovascular
Studied dose
2 mg/kg · intravenous · Short-term infusionAs given in this study (human).
Measurements
Left ventricular stroke work
42.5 g.m
Baseline (+/- 17.9)
Left ventricular stroke work
48.9 g.m
60 mins after methylene blue (+/- 14.5)
Source sentences
Summary
Left ventricular stroke work increased from 42.5 +/- 17.9 to 48.9 +/- 14.5 g.m after 60 mins (p < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective clinical trial.
Summary · context
Fourteen patients with severe septic shock requiring adrenergic therapy.
Summary · context
Hemodynamic measurements were obtained at baseline, and 30, 60, and 90 mins after the infusion of 2 mg/kg of methylene blue.
Report a problemFND-0753255907
08HumanNon-randomized trialEfficacy outcome
In patients with septic shock, methylene blue reduced arterial lactate concentration from baseline.
In plain wordsMethylene blue reduced arterial lactate compared with baseline in patients with septic shock.
Peptide
Methylene blue
Outcome
DecreaseArterial lactate concentration
Study
n = 14
Comparator
Baseline
Outcome group
Metabolic pathways and metabolomics · Metabolic and weight
Studied dose
2 mg/kg · intravenous · Short-term infusionAs given in this study (human).
Measurements
Arterial lactate concentration
3.4 mmol/L
Baseline (+/- 1.4)
Arterial lactate concentration
2.7 mmol/L
After methylene blue (+/- 1.3); time point not stated in sentence
Source sentences
Summary
Arterial lactate concentration decreased from 3.4 +/- 1.4 to 2.7 +/- 1.3 mmol/L (p < .05).
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective clinical trial.
Summary · context
Fourteen patients with severe septic shock requiring adrenergic therapy.
Summary · context
Hemodynamic measurements were obtained at baseline, and 30, 60, and 90 mins after the infusion of 2 mg/kg of methylene blue.
Report a problemFND-0753255908
09HumanNon-randomized trialSafety outcome
In patients with septic shock, no adverse effect was observed after methylene blue.
In plain wordsNo adverse effect was observed after methylene blue in patients with septic shock.
Peptide
Methylene blue
Outcome
Not applicableAdverse effects
Study
n = 14
Outcome group
Adverse events · Whole body
Studied dose
2 mg/kg · intravenous · Short-term infusionAs given in this study (human).
Source sentences
Summary
No adverse effect was observed.
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective clinical trial.
Summary · context
Fourteen patients with severe septic shock requiring adrenergic therapy.
Summary · context
Hemodynamic measurements were obtained at baseline, and 30, 60, and 90 mins after the infusion of 2 mg/kg of methylene blue.
Report a problemFND-0753255910
10HumanNon-randomized trialEfficacy outcome
In six septic shock patients, a second methylene blue dose produced a response similar to the transient initial response.
In plain wordsA second methylene blue dose was followed by a similar response in six patients with septic shock.
Peptide
Methylene blue
Outcome
Not applicableResponse to second dose
Study
n = 6
Comparator
Response to first dose
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
Since these effects were transient, a second dose of methylene blue was administered 90 mins later to six patients and was followed by a similar response.
3 context sentences(design, population, supporting numbers)
Summary · context
Prospective clinical trial.
Summary · context
Fourteen patients with severe septic shock requiring adrenergic therapy.
Summary · context
Hemodynamic measurements were obtained at baseline, and 30, 60, and 90 mins after the infusion of 2 mg/kg of methylene blue.
Report a problemFND-0753255909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.